Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Davunetide / NAP.

Research draft

Davunetide, also called NAP, is an ADNP-derived experimental neuroprotective peptide.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Davunetide, also called NAP, is an ADNP-derived experimental neuroprotective peptide.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It interacts with microtubule-related cellular processes.

Human research

A randomised progressive supranuclear palsy trial did not establish clinical benefit. This negative result remains part of the profile.

Preclinical & other research

Cell work investigated microtubule protection and tau-related mechanisms.

Safety & unknowns

Experimental protection does not guarantee clinical efficacy or long-term safety.

Regulatory status

Investigational; no approved neurodegenerative indication is established here.

Reported use & evidence

Research profile draft

The supplied Davunetide / NAP profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds